Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$155.14M$155.14M+51.9% vs Q3 2019 Net Income$40.00M$40.00M+38.6% vs Q3 2019 EPS Diluted$0.74$0.74+37.0% vs Q3 2019 Operating Income$56,140,000+41.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$5,437,000−85.4% Margins · derivedOperating margin36.2%−2.7 pt vs Q3 2019
Net margin25.8%−2.5 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end